Next Article in Journal
The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology
Next Article in Special Issue
ZEB1 in Pancreatic Cancer
Previous Article in Journal
The Role of Macrophage Migration Inhibitory Factor (MIF) in Ultraviolet Radiation-Induced Carcinogenesis
Previous Article in Special Issue
Neural Invasion in Pancreatic Cancer: The Past, Present and Future
Cancers 2010, 2(3), 1565-1575; doi:10.3390/cancers2031565
Review

Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma

 and *
Received: 28 July 2010; in revised form: 5 August 2010 / Accepted: 6 August 2010 / Published: 9 August 2010
(This article belongs to the Special Issue Pancreatic Cancer)
View Full-Text   |   Download PDF [138 KB, uploaded 9 August 2010]
Abstract: Survival in patients with unresectable pancreatic carcinoma is poor. Studies by Mayo Clinic and the Gastrointestinal Tumor Study Group (GITSG) have established combined modality treatment with chemotherapy and radiation as the standard of care. Use of gemcitabine-based chemotherapy alone has also been shown to provide a benefit, but 5‑year overall survival still remains less than 5%. Conventional radiotherapy is traditionally delivered over a six week period and high toxicity is seen with the concomitant use of chemotherapy. In contrast, SBRT can be delivered in 3–5 days and, when used as a component of combined modality therapy with gemcitabine, disruption to the timely delivery of chemotherapy is minimal. Early single-institution reports of SBRT for unresectable pancreatic carcinoma demonstrate excellent local control with acceptable toxicity. Use of SBRT in unresectable pancreatic carcinoma warrants further investigation in order to improve the survival of patients with historically poor outcomes.
Keywords: stereotactic radiotherapy; radiotherapy; pancreatic neoplasms stereotactic radiotherapy; radiotherapy; pancreatic neoplasms
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Stauder, M.C.; Miller, R.C. Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma. Cancers 2010, 2, 1565-1575.

AMA Style

Stauder MC, Miller RC. Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma. Cancers. 2010; 2(3):1565-1575.

Chicago/Turabian Style

Stauder, Michael C.; Miller, Robert C. 2010. "Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma." Cancers 2, no. 3: 1565-1575.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert